Document Detail


T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy.
MedLine Citation:
PMID:  21857148     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.
Authors:
Norihisa Katayama; Mitsuhiro Takemoto; Kotaro Yoshio; Kuniaki Katsui; Tatsuya Uesugi; Yasutomo Nasu; Toshi Matsushita; Mitsumasa Kaji; Hiromi Kumon; Susumu Kanazawa
Related Documents :
17186248 - Evaluation of the anterior ethmoidal artery by 3d dual volume rotational digital subtra...
7568828 - Hemifacial spasm: three-dimensional mr images in the evaluation of neurovascular compre...
16483278 - Computer-assisted intraaneurysmal thrombus visualization.
22249308 - Modic type i change may predict rapid progressive, deforming disc degeneration: a prosp...
17317948 - Granulomatous pachymeningitis around the sella turcica (tolosa-hunt syndrome) involving...
21111458 - Renal tissue ablation with irreversible electroporation: preliminary results in a porci...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2011-08-20
Journal Detail:
Title:  Journal of radiation research     Volume:  52     ISSN:  1349-9157     ISO Abbreviation:  J. Radiat. Res.     Publication Date:  2011  
Date Detail:
Created Date:  2011-09-28     Completed Date:  2012-01-26     Revised Date:  2012-03-28    
Medline Journal Info:
Nlm Unique ID:  0376611     Medline TA:  J Radiat Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  680-4     Citation Subset:  IM    
Affiliation:
Department of Radiology, Japanese Red Cross Society Himeji Hospital, Japan. n-katayama@bea.hi-ho.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Brachytherapy*
Humans
Iodine Radioisotopes / administration & dosage,  therapeutic use
Magnetic Resonance Imaging
Male
Prostatic Neoplasms / radiography,  radiotherapy*
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Tomography, X-Ray Computed
Chemical
Reg. No./Substance:
0/Iodine Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma.
Next Document:  Phosphorylation of Ataxin-10 by polo-like kinase 1 is required for cytokinesis.